Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 39.02 percent increase over losses of $(0.41) per
Recursion lost more money per share than experts thought it would, and made way less sales than expected. When a company misses on both numbers, it's a sign to watch whether their new medicines are actually working and selling.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.